Not finding it? Sign in to also search OpenAlex live.
-
Autologous haematopoietic stem-cell transplantation versus bortezomib–melphalan–prednisone, with or without bortezomib–lenalidomide–dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study2020 The Lancet Haematology article Medicine Multiple Myeloma Research and Treatments Open access cited by 2 patents
Michèle Cavo, Francesca Gay, Meral Beksaç, Lucia Pantani, Maria Teresa Petrucci, Meletios Athanasios Dimopoulos, +54 more
384citations -
Lenalidomide-rituximab or lenalidomide-rituximab-bendamustine for relapsed/refractory follicular lymphoma: primary and final analysis of the randomized phase II HOVON110/ReBeL study
Marie José Kersten, M Dreyling, Kim Linton, Dana Chitu, Gerben J.C. Zwezerijnen, Sanne H. Tonino, +32 more
0citations -
Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial
Thierry T.F. Facon, Shaji Kunnathu Kumar, Torben Plesner, Robert Zygmunt Orlowski, Philippe Moreau, Nizar Jacques Bahlis, +23 more
376citations -
Poster: MM-155: Phase 3 MAIA Study: Overall Survival (OS) Results with Daratumumab, Lenalidomide, and Dexamethasone (D-Rd) vs Lenalidomide and Dexamethasone (Rd) in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma (TIE-NDMM)
Robert Zygmunt Orlowski, Thierry T.F. Facon, Shaji Kunnathu Kumar, Torben Plesner, Philippe Moreau, Nizar Jacques Bahlis, +23 more
0citations -
Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone Induction Therapy for Transplant-Eligible Newly Diagnosed Multiple Myeloma: Final Part 1 Analysis of the GMMG-HD7 Trial2024 Journal of Clinical Oncology article Medicine Multiple Myeloma Research and Treatments Open access
Elias Karl Mai, Uta Bertsch, Ema Požek, Roland R. Fenk, Britta Besemer, Christine Hanoun, +71 more
80citations -
Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma2023 New England Journal of Medicine article Medicine Multiple Myeloma Research and Treatments Open access cited by 1 patent
Pieter Sonneveld, Meletios Athanasios Dimopoulos, Mario Boccadoro, Hang Quach, P. Joy Ho, Meral Beksaç, +37 more
588citations -
Long-Term Outcome of a Prospective Randomized Trial Comparing Continuous Lenalidomide/Dexamethasone with Lenalidomide/Dexamethasone Induction, MEL140 with Autologous Blood Stem Cell Transplantation and Single Agent Lenalidomide Maintenance in Patients of Age 60-75 Years with Newly Diagnosed Multiple Myeloma
Christian Straka, Kerstin Schaefer‐Eckart, Bernd Hertenstein, Florian C. Bassermann, Hans Jürgen Salwender, Christian H. Langer, +32 more
17citations -
Plain Language Summary of the MAIA Study of Daratumumab Plus Lenalidomide and Dexamethasone for the Treatment of People with Newly Diagnosed Multiple Myeloma
Thierry T.F. Facon, Shaji Kunnathu Kumar, Torben Plesner, Robert Zygmunt Orlowski, Philippe Moreau, Nizar Jacques Bahlis, +18 more
2citations -
Phase 3 Randomized Study of Daratumumab (DARA) + Bortezomib, Lenalidomide, and Dexamethasone (VRd) Versus Vrd Alone in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Who Are Eligible for Autologous Stem Cell Transplantation (ASCT): Primary Results of the Perseus Trial
Pieter Sonneveld, Meletios Athanasios Dimopoulos, Mario Boccadoro, Hang Quach, P. Joy Ho, Meral Beksaç, +37 more
18citations -
P957: CARFILZOMIB, LENALIDOMIDE, DEXAMETHASONE FOLLOWED BY A SECOND AUTO-HCT IS AN EFFECTIVE STRATEGY IN FIRST RELAPSE MULTIPLE MYELOMA: A STUDY OF THE CHRONIC MALIGNANCIES WORKING PARTY OF EBMT
Romain Tilmont, Ibrahim Yakoub‐Agha, Diderik-Jan Eikema, Nienke Zinger, Mathias Haenel, Nicolaas PM Schaap, +18 more
1citations -
Daratumumab (DARA) Plus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Patients with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of Griffin after 12 Months of Maintenance Therapy
Jonathan L. Kaufman, Jacob P. Laubach, Douglas Weston Sborov, Brandi Reeves, Cesar Rodriguez, Ajai Chari, +21 more
24citations -
Carfilzomib, lenalidomide and dexamethasone followed by a second ASCT is an effective strategy in first relapse multiple myeloma: a study on behalf of the Chronic malignancies working party of the EBMT2023 Bone Marrow Transplantation article Medicine Multiple Myeloma Research and Treatments Open access
Rémi Tilmont, Ibrahim Yakoub‐Agha, Diderik-Jan Eikema, Nienke Zinger, Mathias Haenel, Nicolaas PM Schaap, +20 more
2citations -
Daratumumab plus lenalidomide, bortezomib and dexamethasone in newly diagnosed multiple myeloma: Analysis of vascular thrombotic events in the GRIFFIN study2022 British Journal of Haematology article Medicine Multiple Myeloma Research and Treatments Open access
Douglas Weston Sborov, Muhamed Baljević, Brandi Reeves, Jacob P. Laubach, Yvonne Adeduni Efebera, Cesar Rodriguez, +15 more
24citations